<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332784</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-925-1001</org_study_id>
    <secondary_id>U1111-1201-6634</secondary_id>
    <secondary_id>JapicCTI-173756</secondary_id>
    <nct_id>NCT03332784</nct_id>
  </id_info>
  <brief_title>Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy</brief_title>
  <official_title>A Phase 1 Study of TAK-925 to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of TAK-925 in Healthy Adult and Elderly Volunteers and Patients With Narcolepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate safety, tolerability, and pharmacokinetics of&#xD;
      TAK-925 when a single dose of TAK-925 is administered to healthy adult participants, healthy&#xD;
      elderly participants and patients with type 1 narcolepsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Orexins are neuropeptides that play a role in the regulation of sleep and wakefulness. In&#xD;
      type 1 narcolepsy, there is a loss of orexin producing neurons in the brain. The&#xD;
      investigational drug, TAK-925, is an orexin 2 receptor agonist that is being tested in&#xD;
      healthy adult participants, healthy elderly participants and patients with narcolepsy in&#xD;
      order to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single intravenous&#xD;
      administration.&#xD;
&#xD;
      The study will enroll approximately 20 healthy participants and 16 healthy elderly&#xD;
      participants in Part 1 of the study and approximately 20 patients with narcolepsy in Part 2.&#xD;
&#xD;
      In Part 1, the study consists of 4 cohorts of 8 or 4 participants each. Participants will be&#xD;
      randomly assigned (by chance, like flipping a coin) to one of the following treatment groups&#xD;
      to receive TAK-925 or placebo:&#xD;
&#xD;
      - Part 1, Cohort 1; TAK-925 (Dose Level 1, 3, 5), Cohort 2; TAK-925 (Dose Level 2, 4, 6),&#xD;
      Cohort 3 and 4; TAK-925 (Dose Level 5)&#xD;
&#xD;
      For Cohort 1-4, healthy adult and elderly participants will be administered TAK-925 or&#xD;
      placebo once in each cohort or dose level. The dose at the start (Cohort 1 dose level 1) is 7&#xD;
      mg of TAK-925 and following doses in Cohorts 1-4 will be determined based on available data&#xD;
      from previous Cohorts/dose levels.&#xD;
&#xD;
      In Part 2 of the study, the study consists of 3 cohorts of 4 to 12 patients with narcolepsy.&#xD;
      Patients will be randomly assigned to one of the treatment groups of Cohort 5-7 and will be&#xD;
      administered TAK-925 or placebo once in each cohort. The dose of TAK-925 in Cohort 5-7 is TBD&#xD;
      and will be decided based on available data from Part 1 and previous Cohorts.&#xD;
&#xD;
      - Part 2, Cohort 5-7&#xD;
&#xD;
      This multi-center trial will be conducted in Japan. Participants will make multiple visits to&#xD;
      the clinic. Visits in Part 1 will include a screening period (Day -28 to -2), Check-in on Day&#xD;
      -1, Treatment period (Day 1 and 2), and follow-up visit on Day 7. In Part 2 of the study, the&#xD;
      visits include a screening period (Day -42 to -2), Check-in on Day -1, Cross-over period (Day&#xD;
      1 to 4), and follow-up visit on Day 7.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2017</start_date>
  <completion_date type="Actual">September 4, 2018</completion_date>
  <primary_completion_date type="Actual">September 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience at Least One TEAE Related to Vital Signs</measure>
    <time_frame>Baseline up to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience at Least One TEAE Related to Body Weight</measure>
    <time_frame>Baseline up to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience at Least One TEAE Related to 12-lead Electrocardiogram (ECG)</measure>
    <time_frame>Baseline up to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience at Least One TEAE Related to Clinical Laboratory Tests</measure>
    <time_frame>Baseline up to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, Cmax: Maximum Observed Plasma Concentration for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Cmax: Maximum Observed Plasma Concentration for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, Ceoi: Concentration at the End of Infusion for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Ceoi: Concentration at the End of Infusion for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, t1/2z: Terminal Disposition Phase Half-life of TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, t1/2z: Terminal Disposition Phase Half-life of TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-925</measure>
    <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-925</measure>
    <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, Vz: Volume of Distribution During the Terminal Phase After Intravenous Administration for TAK-925</measure>
    <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Vz: Volume of Distribution During the Terminal Phase After Intravenous Administration for TAK-925</measure>
    <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, CL: Total Clearance After Intravenous Administration for TAK-925</measure>
    <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, CL: Total Clearance After Intravenous Administration for TAK-925</measure>
    <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, Ae(0-24): Amount of TAK-925 and Its Metabolites M1 and M2 Excreted in Urine From Time 0 to Time 24</measure>
    <time_frame>Day 1 pre-infusion and 0-9 hours after the start of infusion and at 0-3, 3-6, 6-15 and 15-24 hours post-infusion</time_frame>
    <description>Urine assessments were done only in Part 1, as planned.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, Fe(0-24): Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time 24 for TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Day 1 pre-infusion and 0-9 hours after the start of infusion and at 0-3, 3-6, 6-15 and 15-24 hours post-infusion</time_frame>
    <description>Urine assessments were done only in Part 1, as planned.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, CLR: Renal Clearance of TAK-925 and Its Metabolites M1 and M2</measure>
    <time_frame>Day 1 pre-infusion and 0-9 hours after the start of infusion and at 0-3, 3-6 and 6-15 hours post-infusion</time_frame>
    <description>Urine assessments were done only in Part 1, as planned.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, R(CSF/Plasma,ss): Cerebrospinal Fluid/Plasma Drug Concentration at Steady State for TAK-925 and Its Metabolites M1 and M2 in Cohort 4</measure>
    <time_frame>Day 1 at 6 hours after start of infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Average Sleep Latency in Maintenance of Wakefulness Test (MWT)</measure>
    <time_frame>Days 1 and 3 up to 8 hours following the start of infusion</time_frame>
    <description>The MWT is a validated objective measure that evaluates a person's ability to remain awake under soporific conditions for a defined period of time. This tendency to fall asleep is measured via electroencephalography-derived sleep latency. Sleep onset is defined as the first epoch of greater than 15 seconds of cumulative sleep in a 30-second epoch. Trials were ended after 40 minutes if no sleep occurs, or after unequivocal sleep, defined as 3 consecutive epochs of stage 1 sleep, or 1 epoch of any other stage of sleep. If no sleep has been observed according to these rules, then the latency is defined as 40 minutes. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Healthy Participants and Patients With Narcolepsy</condition>
  <arm_group>
    <arm_group_label>Part 1: TAK-925 (Cohort 1; Dose Level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Healthy adults will be enrolled in double blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: TAK-925 (Cohort 2; Dose Level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 2). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: TAK-925 (Cohort 1; Dose Level 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 3). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: TAK-925 (Cohort 2; Dose Level 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 4). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: TAK-925 (Cohort 1; Dose Level 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: TAK-925 (Cohort 2; Dose Level 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 6). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo (Cohort 1-2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-925 Placebo, Intravenous single administration. Healthy adults will be enrolled in double blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: TAK-925 (Cohort 3; Dose Level 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy elderly participants will be enrolled in double blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo (Cohort 3)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-925 Placebo, Intravenous single administration. Healthy elderly participants will be enrolled in double blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: TAK-925 (Cohort 4; Dose Level 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy adults will be enrolled in non-blinded manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: TAK-925 TBD (Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Dose in Cohort 5 will be based on safety and tolerability in the Part 1. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: TAK-925 TBD (Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Dose in Cohort 6 TBD based on safety, tolerability, PK data, and results of the Maintenance Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: TAK-925 TBD (Cohort 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-925, Intravenous single administration. Dose in Cohort 7 TBD based on safety, tolerability, PK data, and results of the Maintenance of Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo (Cohort 5-7)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-925 Placebo, Intravenous single administration. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-925</intervention_name>
    <description>TAK-925 Intravenous Infusion</description>
    <arm_group_label>Part 1: TAK-925 (Cohort 1; Dose Level 1)</arm_group_label>
    <arm_group_label>Part 1: TAK-925 (Cohort 1; Dose Level 3)</arm_group_label>
    <arm_group_label>Part 1: TAK-925 (Cohort 1; Dose Level 5)</arm_group_label>
    <arm_group_label>Part 1: TAK-925 (Cohort 2; Dose Level 2)</arm_group_label>
    <arm_group_label>Part 1: TAK-925 (Cohort 2; Dose Level 4)</arm_group_label>
    <arm_group_label>Part 1: TAK-925 (Cohort 2; Dose Level 6)</arm_group_label>
    <arm_group_label>Part 1: TAK-925 (Cohort 3; Dose Level 5)</arm_group_label>
    <arm_group_label>Part 1: TAK-925 (Cohort 4; Dose Level 5)</arm_group_label>
    <arm_group_label>Part 2: TAK-925 TBD (Cohort 5)</arm_group_label>
    <arm_group_label>Part 2: TAK-925 TBD (Cohort 6)</arm_group_label>
    <arm_group_label>Part 2: TAK-925 TBD (Cohort 7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TAK-925 Placebo Intravenous Infusion</description>
    <arm_group_label>Part 1: Placebo (Cohort 1-2)</arm_group_label>
    <arm_group_label>Part 1: Placebo (Cohort 3)</arm_group_label>
    <arm_group_label>Part 2: Placebo (Cohort 5-7)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy adult participants and Healthy elderly participants:&#xD;
&#xD;
        - Participant weighs at least 50 kilogram (kg) (Healthy adults participants) / 40 kg&#xD;
        (Healthy elderly participants) and has a body mass index (BMI) from 18.5 to 30 kilogram per&#xD;
        square meter (kg/m^2), inclusive at Screening.&#xD;
&#xD;
        Narcolepsy patients:&#xD;
&#xD;
          -  Patient weighs at least 40 kg inclusive at Screening.&#xD;
&#xD;
          -  A diagnosis of narcolepsy Type 1, as defined by the International Classification of&#xD;
             Sleep Disorders, Third Edition (ICSD-3).&#xD;
&#xD;
          -  HLA narcolepsy test positivity.&#xD;
&#xD;
          -  At Day -1, Epworth sleepiness scale (ESS) score greater than or equal to (&gt;=) 10&#xD;
&#xD;
          -  Blood pressure less than (&lt;) 140 systolic and &lt; 90 diastolic. The patient may have a&#xD;
             history of hypertension and be on antihypertensive medication treatment as long as the&#xD;
             BP meets these criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Participants:&#xD;
&#xD;
          -  Participant has a history of drug abuse (defined as any illicit drug use) or a history&#xD;
             of alcohol abuse within 2 years prior to the Screening visit.&#xD;
&#xD;
          -  Past or current epilepsy, convulsion, tremor or the disorders of related symptoms.&#xD;
&#xD;
          -  Has a lifetime history of major psychiatric disorder, such as major depressive&#xD;
             disorder, bipolar disorder, or schizophrenia.&#xD;
&#xD;
        HV (only Cohort 4):&#xD;
&#xD;
        - Participant has had CSF collection performed within 14 days prior to check-in (Day -1).&#xD;
&#xD;
        Narcolepsy patients&#xD;
&#xD;
          -  Medical disorder associated with excessive sleepiness other than narcolepsy (including&#xD;
             sleep apnea syndrome).&#xD;
&#xD;
          -  Excessive caffeine (greater than [&gt;] 400 milligram per day [mg/day]) use one week&#xD;
             prior to study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sumida Hospital</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hakata Clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PS Clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <results_first_submitted>September 2, 2020</results_first_submitted>
  <results_first_submitted_qc>October 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2020</results_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03332784/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03332784/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 3 investigative sites in Japan from 04 November 2017 to 04 September 2018.</recruitment_details>
      <pre_assignment_details>Healthy adult and elderly participants were enrolled to receive TAK-925 or placebo in Cohorts 1 and 2 under alternating panel design and in Cohorts S1, S2, 3, and 4 under parallel design of Part 1, and participants with type 1 narcolepsy were enrolled to receive TAK-925 or placebo in a 2-period cross-over design in Cohorts 5, 6, and 7 of Part 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1 Cohort 1: TAK-925 7 mg + TAK-925 28 mg + TAK-925 112 mg</title>
          <description>TAK-925 7 milligram (mg), infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 28 mg infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 112 mg infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group A in double-blind, alternating panel.</description>
        </group>
        <group group_id="P2">
          <title>Part 1 Cohort 1: TAK-925 7 mg + TAK-925 28 mg + Placebo</title>
          <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 28 mg infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group B in double-blind, alternating panel.</description>
        </group>
        <group group_id="P3">
          <title>Part 1 Cohort 1: TAK-925 7 mg + Placebo + TAK-925 112 mg</title>
          <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 112 mg, infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group C in double-blind, alternating panel.</description>
        </group>
        <group group_id="P4">
          <title>Part 1 Cohort 1: Placebo + TAK-925 28 mg + TAK-925 112 mg</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 28 mg, infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 112 mg, infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group D in double-blind, alternating panel.</description>
        </group>
        <group group_id="P5">
          <title>Part 1 Cohort 2:TAK-925 14 mg +TAK-925 56 mg +TAK-925 134.4 mg</title>
          <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 56 mg infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 134.4 mg infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group E in double-blind, alternating panel.</description>
        </group>
        <group group_id="P6">
          <title>Part 1 Cohort 2: TAK-925 14 mg + TAK-925 56 mg + Placebo</title>
          <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 56 mg infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 3 in Group F in healthy adults in double-blind, alternating panel.</description>
        </group>
        <group group_id="P7">
          <title>Part 1 Cohort 2: TAK-925 14 mg + Placebo + TAK-925 134.4 mg</title>
          <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 134.4 mg infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group G in double-blind, alternating panel.</description>
        </group>
        <group group_id="P8">
          <title>Part 1 Cohort 2: Placebo + TAK-925 56 mg + TAK-925 134.4 mg</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 56 mg infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 134.4 mg infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group H in double-blind, alternating panel.</description>
        </group>
        <group group_id="P9">
          <title>Part 1 Cohort S1-S2: Pooled Placebo</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
        </group>
        <group group_id="P10">
          <title>Part 1 Cohort S1: TAK-925 180 mg</title>
          <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
        </group>
        <group group_id="P11">
          <title>Part 1 Cohort S2: TAK-925 240 mg</title>
          <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
        </group>
        <group group_id="P12">
          <title>Part 1 Cohort 3: Placebo</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
        </group>
        <group group_id="P13">
          <title>Part 1 Cohort 3: TAK-925 112 mg</title>
          <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
        </group>
        <group group_id="P14">
          <title>Part 1 Cohort 4: TAK-925 112 mg</title>
          <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
        </group>
        <group group_id="P15">
          <title>Part 2 Cohort 5: TAK-925 44.8 mg + Placebo</title>
          <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 2 (Day 3) in participants with type 1 narcolepsy in Group I under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications.</description>
        </group>
        <group group_id="P16">
          <title>Part 2 Cohort 5: Placebo + TAK-925 44.8 mg</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 44.8 mg, infusion, intravenously, once on Day 1 of Period 2 (Day 3) in participants with type 1 narcolepsy in Group J under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications.</description>
        </group>
        <group group_id="P17">
          <title>Part 2 Cohort 6: TAK-925 11.2 mg + Placebo</title>
          <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 2 (Day 3) in participants with type 1 narcolepsy in Group K under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications.</description>
        </group>
        <group group_id="P18">
          <title>Part 2 Cohort 6: Placebo + TAK-925 11.2 mg</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 11.2 mg, infusion, intravenously, once on Day 1 Period 2 (Day 3) in participants with type 1 narcolepsy in Group L under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications.</description>
        </group>
        <group group_id="P19">
          <title>Part 2 Cohort 7: TAK-925 5 mg + Placebo</title>
          <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 2 (Day 3) in participants with type 1 narcolepsy in Group M under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications.</description>
        </group>
        <group group_id="P20">
          <title>Part 2 Cohort 7: Placebo + TAK-925 5 mg</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 5 mg, infusion, intravenously, once on Day 1 of Period 2 (Day 3) in participants with type 1 narcolepsy in Group N under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Parts 1 and 2 - Period 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="2">A washout period of 7 days was required before the dosing on Day 1 for prior medications.</participants>
                <participants group_id="P16" count="2">A washout period of 7 days was required before the dosing on Day 1 for prior medications.</participants>
                <participants group_id="P17" count="2">A washout period of 7 days was required before the dosing on Day 1 for prior medications.</participants>
                <participants group_id="P18" count="2">A washout period of 7 days was required before the dosing on Day 1 for prior medications.</participants>
                <participants group_id="P19" count="3">A washout period of 7 days was required before the dosing on Day 1 for prior medications.</participants>
                <participants group_id="P20" count="3">A washout period of 7 days was required before the dosing on Day 1 for prior medications.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="3"/>
                <participants group_id="P20" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Parts 1 and 2- Period 2 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P10" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P11" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P12" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P13" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P14" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="3"/>
                <participants group_id="P20" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="3"/>
                <participants group_id="P20" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1- Period 3 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P10" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P11" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P12" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P13" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P14" count="0">Part 1 Cohorts S1-2, 3, and 4 participants did not continue in subsequent periods after Period 1.</participants>
                <participants group_id="P15" count="0">Part 2 participants did not continue in subsequent periods after Period 2.</participants>
                <participants group_id="P16" count="0">Part 2 participants did not continue in subsequent periods after Period 2.</participants>
                <participants group_id="P17" count="0">Part 2 participants did not continue in subsequent periods after Period 2.</participants>
                <participants group_id="P18" count="0">Part 2 participants did not continue in subsequent periods after Period 2.</participants>
                <participants group_id="P19" count="0">Part 2 participants did not continue in subsequent periods after Period 2.</participants>
                <participants group_id="P20" count="0">Part 2 participants did not continue in subsequent periods after Period 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1 Cohort 1: TAK-925 7 mg + TAK-925 28 mg + TAK-925 112 mg</title>
          <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 28 mg infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 112 mg infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group A in double-blind, alternating panel.</description>
        </group>
        <group group_id="B2">
          <title>Part 1 Cohort 1: TAK-925 7 mg + TAK-925 28 mg + Placebo</title>
          <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 28 mg infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group B in double-blind, alternating panel.</description>
        </group>
        <group group_id="B3">
          <title>Part 1 Cohort 1: TAK-925 7 mg + Placebo + TAK-925 112 mg</title>
          <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 112 mg, infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group C in double-blind, alternating panel.</description>
        </group>
        <group group_id="B4">
          <title>Part 1 Cohort 1: Placebo + TAK-925 28 mg + TAK-925 112 mg</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 28 mg, infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 112 mg, infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group D in double-blind, alternating panel.</description>
        </group>
        <group group_id="B5">
          <title>Part 1 Cohort 2:TAK-925 14 mg +TAK-925 56 mg +TAK-925 134.4 mg</title>
          <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 56 mg infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 134.4 mg infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group E in double-blind, alternating panel.</description>
        </group>
        <group group_id="B6">
          <title>Part 1 Cohort 2: TAK-925 14 mg + TAK-925 56 mg + Placebo</title>
          <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 56 mg infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 3 in Group F in healthy adults in double-blind, alternating panel.</description>
        </group>
        <group group_id="B7">
          <title>Part 1 Cohort 2: TAK-925 14 mg + Placebo + TAK-925 134.4 mg</title>
          <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 134.4 mg infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group G in double-blind, alternating panel.</description>
        </group>
        <group group_id="B8">
          <title>Part 1 Cohort 2: Placebo + TAK-925 56 mg + TAK-925 134.4 mg</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 56 mg infusion, intravenously, once on Day 1 of Period 2, further followed by TAK-925 134.4 mg infusion, intravenously, once on Day 1 of Period 3 in healthy adults in Group H in double-blind, alternating panel.</description>
        </group>
        <group group_id="B9">
          <title>Part 1 Cohort S1-S2: Pooled Placebo</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
        </group>
        <group group_id="B10">
          <title>Part 1: Cohort S1 TAK-925 180 mg</title>
          <description>TAK-925 180 mg, infusion, intravenously, once, over 9 hours on Day 1 in healthy adults in double-blind, parallel group.</description>
        </group>
        <group group_id="B11">
          <title>Part 1: Cohort S2 TAK-925 240 mg</title>
          <description>TAK-925 240 mg, infusion, intravenously, once, over 9 hours on Day 1 in healthy adults in double-blind, parallel group.</description>
        </group>
        <group group_id="B12">
          <title>Part 1: Cohort 3 Placebo</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once, over 9 hours on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
        </group>
        <group group_id="B13">
          <title>Part 1: Cohort 3 TAK-925 112 mg</title>
          <description>TAK-925 112 mg, infusion, intravenously, once, over 9 hours on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
        </group>
        <group group_id="B14">
          <title>Part 1: Cohort 4 TAK-925 112 mg</title>
          <description>TAK-925 112 mg, infusion, intravenously, once, over 9 hours on Day 1 in healthy adults in unblinded manner.</description>
        </group>
        <group group_id="B15">
          <title>Part 2 Cohort 5: TAK-925 44.8 mg + Placebo</title>
          <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 2 (Day 3) in participants with type 1 narcolepsy in Group I under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications.</description>
        </group>
        <group group_id="B16">
          <title>Part 2 Cohort 5, Part J: TAK-925 Placebo + 44.8 mg</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 44.8 mg, infusion, intravenously, once on Day 1 of Period 2 (Day 3) in participants with type 1 narcolepsy in Group J under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications.</description>
        </group>
        <group group_id="B17">
          <title>Part 2 Cohort 6: TAK-925 11.2 mg + Placebo</title>
          <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 2 (Day 3) in participants with type 1 narcolepsy in Group K under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications.</description>
        </group>
        <group group_id="B18">
          <title>Part 2 Cohort 6: Placebo + TAK-925 11.2 mg</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 11.2 mg, infusion, intravenously, once on Day 1 Period 2 (Day 3) in participants with type 1 narcolepsy in Group L under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications.</description>
        </group>
        <group group_id="B19">
          <title>Part 2 Cohort 7: TAK-925 5 mg + Placebo</title>
          <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 2 (Day 3) in participants with type 1 narcolepsy in Group M under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications.</description>
        </group>
        <group group_id="B20">
          <title>Part 2 Cohort 7: Placebo + TAK-925 5 mg</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 of Period 1, followed by TAK-925 5 mg, infusion, intravenously, once on Day 1 of Period 2 (Day 3) in participants with type 1 narcolepsy in Group N under 2-period crossover design. A washout period of 7 days was required before the dosing on Day 1 for prior medications</description>
        </group>
        <group group_id="B21">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="2"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="2"/>
            <count group_id="B8" value="2"/>
            <count group_id="B9" value="4"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="2"/>
            <count group_id="B13" value="6"/>
            <count group_id="B14" value="4"/>
            <count group_id="B15" value="2"/>
            <count group_id="B16" value="2"/>
            <count group_id="B17" value="2"/>
            <count group_id="B18" value="2"/>
            <count group_id="B19" value="3"/>
            <count group_id="B20" value="3"/>
            <count group_id="B21" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="2"/>
                    <count group_id="B6" value="2"/>
                    <count group_id="B7" value="2"/>
                    <count group_id="B8" value="2"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="6"/>
                    <count group_id="B12" value="2"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="4"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="2"/>
                    <count group_id="B17" value="2"/>
                    <count group_id="B18" value="2"/>
                    <count group_id="B19" value="3"/>
                    <count group_id="B20" value="3"/>
                    <count group_id="B21" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="5.66"/>
                    <measurement group_id="B2" value="25.5" spread="4.95"/>
                    <measurement group_id="B3" value="22.0" spread="2.83"/>
                    <measurement group_id="B4" value="30.0" spread="4.24"/>
                    <measurement group_id="B5" value="24.5" spread="3.54"/>
                    <measurement group_id="B6" value="28.0" spread="9.90"/>
                    <measurement group_id="B7" value="28.5" spread="9.19"/>
                    <measurement group_id="B8" value="34.5" spread="4.95"/>
                    <measurement group_id="B9" value="24.8" spread="4.57"/>
                    <measurement group_id="B10" value="24.5" spread="5.75"/>
                    <measurement group_id="B11" value="27.5" spread="6.72"/>
                    <measurement group_id="B12" value="72.5" spread="3.54"/>
                    <measurement group_id="B13" value="67.7" spread="2.94"/>
                    <measurement group_id="B14" value="21.3" spread="0.50"/>
                    <measurement group_id="B15" value="21.5" spread="4.95"/>
                    <measurement group_id="B16" value="33.0" spread="15.56"/>
                    <measurement group_id="B17" value="25.5" spread="7.78"/>
                    <measurement group_id="B18" value="38.5" spread="0.71"/>
                    <measurement group_id="B19" value="42.3" spread="20.11"/>
                    <measurement group_id="B20" value="33.7" spread="4.51"/>
                    <measurement group_id="B21" value="33.7" spread="16.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="2"/>
                    <count group_id="B6" value="2"/>
                    <count group_id="B7" value="2"/>
                    <count group_id="B8" value="2"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="6"/>
                    <count group_id="B12" value="2"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="4"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="2"/>
                    <count group_id="B17" value="2"/>
                    <count group_id="B18" value="2"/>
                    <count group_id="B19" value="3"/>
                    <count group_id="B20" value="3"/>
                    <count group_id="B21" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="3"/>
                    <measurement group_id="B20" value="1"/>
                    <measurement group_id="B21" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="2"/>
                    <measurement group_id="B21" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="0"/>
                    <count group_id="B17" value="0"/>
                    <count group_id="B18" value="0"/>
                    <count group_id="B19" value="0"/>
                    <count group_id="B20" value="0"/>
                    <count group_id="B21" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B21" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="2"/>
                    <count group_id="B6" value="2"/>
                    <count group_id="B7" value="2"/>
                    <count group_id="B8" value="2"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="6"/>
                    <count group_id="B12" value="2"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="4"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="2"/>
                    <count group_id="B17" value="2"/>
                    <count group_id="B18" value="2"/>
                    <count group_id="B19" value="3"/>
                    <count group_id="B20" value="3"/>
                    <count group_id="B21" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="3"/>
                    <measurement group_id="B20" value="3"/>
                    <measurement group_id="B21" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilogram per square meter (kg/m˄2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="2"/>
                    <count group_id="B6" value="2"/>
                    <count group_id="B7" value="2"/>
                    <count group_id="B8" value="2"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="6"/>
                    <count group_id="B12" value="2"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="4"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="2"/>
                    <count group_id="B17" value="2"/>
                    <count group_id="B18" value="2"/>
                    <count group_id="B19" value="3"/>
                    <count group_id="B20" value="3"/>
                    <count group_id="B21" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.25" spread="2.475"/>
                    <measurement group_id="B2" value="22.35" spread="0.919"/>
                    <measurement group_id="B3" value="20.85" spread="2.899"/>
                    <measurement group_id="B4" value="22.10" spread="0.141"/>
                    <measurement group_id="B5" value="21.55" spread="2.616"/>
                    <measurement group_id="B6" value="20.90" spread="0.424"/>
                    <measurement group_id="B7" value="23.40" spread="2.687"/>
                    <measurement group_id="B8" value="22.15" spread="1.626"/>
                    <measurement group_id="B9" value="22.65" spread="1.912"/>
                    <measurement group_id="B10" value="20.48" spread="0.768"/>
                    <measurement group_id="B11" value="21.05" spread="1.325"/>
                    <measurement group_id="B12" value="23.00" spread="2.263"/>
                    <measurement group_id="B13" value="23.22" spread="3.451"/>
                    <measurement group_id="B14" value="22.03" spread="2.791"/>
                    <measurement group_id="B15" value="32.30" spread="10.041"/>
                    <measurement group_id="B16" value="24.60" spread="2.546"/>
                    <measurement group_id="B17" value="23.60" spread="0.707"/>
                    <measurement group_id="B18" value="26.45" spread="8.697"/>
                    <measurement group_id="B19" value="26.10" spread="7.146"/>
                    <measurement group_id="B20" value="29.57" spread="5.689"/>
                    <measurement group_id="B21" value="23.19" spread="4.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="2"/>
                    <count group_id="B6" value="2"/>
                    <count group_id="B7" value="2"/>
                    <count group_id="B8" value="2"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="6"/>
                    <count group_id="B12" value="2"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="4"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="2"/>
                    <count group_id="B17" value="2"/>
                    <count group_id="B18" value="2"/>
                    <count group_id="B19" value="3"/>
                    <count group_id="B20" value="3"/>
                    <count group_id="B21" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176.0" spread="1.41"/>
                    <measurement group_id="B2" value="167.0" spread="2.83"/>
                    <measurement group_id="B3" value="174.5" spread="2.12"/>
                    <measurement group_id="B4" value="177.0" spread="8.49"/>
                    <measurement group_id="B5" value="170.0" spread="4.24"/>
                    <measurement group_id="B6" value="173.0" spread="1.41"/>
                    <measurement group_id="B7" value="170.0" spread="9.90"/>
                    <measurement group_id="B8" value="171.5" spread="6.36"/>
                    <measurement group_id="B9" value="173.5" spread="5.80"/>
                    <measurement group_id="B10" value="173.0" spread="3.16"/>
                    <measurement group_id="B11" value="168.8" spread="5.00"/>
                    <measurement group_id="B12" value="149.0" spread="0.00"/>
                    <measurement group_id="B13" value="159.5" spread="4.64"/>
                    <measurement group_id="B14" value="171.0" spread="5.89"/>
                    <measurement group_id="B15" value="155.5" spread="0.71"/>
                    <measurement group_id="B16" value="174.5" spread="6.36"/>
                    <measurement group_id="B17" value="171.0" spread="1.41"/>
                    <measurement group_id="B18" value="159.5" spread="2.12"/>
                    <measurement group_id="B19" value="160.7" spread="4.73"/>
                    <measurement group_id="B20" value="168.3" spread="11.55"/>
                    <measurement group_id="B21" value="168.1" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="2"/>
                    <count group_id="B6" value="2"/>
                    <count group_id="B7" value="2"/>
                    <count group_id="B8" value="2"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="6"/>
                    <count group_id="B12" value="2"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="4"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="2"/>
                    <count group_id="B17" value="2"/>
                    <count group_id="B18" value="2"/>
                    <count group_id="B19" value="3"/>
                    <count group_id="B20" value="3"/>
                    <count group_id="B21" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.15" spread="7.707"/>
                    <measurement group_id="B2" value="62.65" spread="0.636"/>
                    <measurement group_id="B3" value="62.90" spread="10.607"/>
                    <measurement group_id="B4" value="69.60" spread="6.930"/>
                    <measurement group_id="B5" value="60.95" spread="5.445"/>
                    <measurement group_id="B6" value="62.45" spread="1.909"/>
                    <measurement group_id="B7" value="68.80" spread="14.849"/>
                    <measurement group_id="B8" value="63.85" spread="8.839"/>
                    <measurement group_id="B9" value="68.73" spread="1.941"/>
                    <measurement group_id="B10" value="61.12" spread="2.860"/>
                    <measurement group_id="B11" value="59.55" spread="6.142"/>
                    <measurement group_id="B12" value="51.30" spread="4.101"/>
                    <measurement group_id="B13" value="58.77" spread="10.388"/>
                    <measurement group_id="B14" value="63.88" spread="7.029"/>
                    <measurement group_id="B15" value="78.45" spread="24.112"/>
                    <measurement group_id="B16" value="74.95" spread="0.071"/>
                    <measurement group_id="B17" value="69.05" spread="1.202"/>
                    <measurement group_id="B18" value="67.70" spread="23.900"/>
                    <measurement group_id="B19" value="67.57" spread="22.212"/>
                    <measurement group_id="B20" value="83.43" spread="15.970"/>
                    <measurement group_id="B21" value="65.20" spread="10.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="2"/>
                    <count group_id="B6" value="2"/>
                    <count group_id="B7" value="2"/>
                    <count group_id="B8" value="2"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="6"/>
                    <count group_id="B12" value="2"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="4"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="2"/>
                    <count group_id="B17" value="2"/>
                    <count group_id="B18" value="2"/>
                    <count group_id="B19" value="3"/>
                    <count group_id="B20" value="3"/>
                    <count group_id="B21" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Non-smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="1"/>
                    <measurement group_id="B21" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Current smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="1"/>
                    <measurement group_id="B21" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="1"/>
                    <measurement group_id="B21" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="2"/>
                    <count group_id="B6" value="2"/>
                    <count group_id="B7" value="2"/>
                    <count group_id="B8" value="2"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="6"/>
                    <count group_id="B12" value="2"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="4"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="2"/>
                    <count group_id="B17" value="2"/>
                    <count group_id="B18" value="2"/>
                    <count group_id="B19" value="3"/>
                    <count group_id="B20" value="3"/>
                    <count group_id="B21" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Daily</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>A Few Times Per Week</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="1"/>
                    <measurement group_id="B21" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>A Few Times Per Month</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-alcoholic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="2"/>
                    <measurement group_id="B21" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="2"/>
                    <count group_id="B6" value="2"/>
                    <count group_id="B7" value="2"/>
                    <count group_id="B8" value="2"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="6"/>
                    <count group_id="B12" value="2"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="4"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="2"/>
                    <count group_id="B17" value="2"/>
                    <count group_id="B18" value="2"/>
                    <count group_id="B19" value="3"/>
                    <count group_id="B20" value="3"/>
                    <count group_id="B21" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Had caffeine consumption</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="3"/>
                    <measurement group_id="B21" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Had no caffeine consumption</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)</title>
        <time_frame>Baseline up to Day 7</time_frame>
        <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1-2: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in Group A to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S1-S2: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O11">
            <title>Part 1 Cohort 3: Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O12">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O13">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
          <group group_id="O14">
            <title>Part 2 Cohort 5-7: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy in Cohort 5 to 7 under 2-period crossover design.</description>
          </group>
          <group group_id="O15">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O16">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O17">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)</title>
          <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="13"/>
                <count group_id="O15" value="4"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="4"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience at Least One TEAE Related to Vital Signs</title>
        <time_frame>Baseline up to Day 7</time_frame>
        <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1-2: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in Group A to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S1-S2: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O11">
            <title>Part 1 Cohort 3: Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O12">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O13">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
          <group group_id="O14">
            <title>Part 2 Cohort 5-7: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy in Cohort 5 to 7 under 2-period crossover design.</description>
          </group>
          <group group_id="O15">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O16">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O17">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience at Least One TEAE Related to Vital Signs</title>
          <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="13"/>
                <count group_id="O15" value="4"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience at Least One TEAE Related to Body Weight</title>
        <time_frame>Baseline up to Day 7</time_frame>
        <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1-2: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in Group A to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S1-S2: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O11">
            <title>Part 1 Cohort 3: Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O12">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O13">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
          <group group_id="O14">
            <title>Part 2 Cohort 5-7: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy in Cohort 5 to 7 under 2-period crossover design.</description>
          </group>
          <group group_id="O15">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O16">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O17">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience at Least One TEAE Related to Body Weight</title>
          <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="13"/>
                <count group_id="O15" value="4"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience at Least One TEAE Related to 12-lead Electrocardiogram (ECG)</title>
        <time_frame>Baseline up to Day 7</time_frame>
        <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1-2: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in Group A to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S1-S2: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O11">
            <title>Part 1 Cohort 3: Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O12">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O13">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
          <group group_id="O14">
            <title>Part 2 Cohort 5-7: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy in Cohort 5 to 7 under 2-period crossover design.</description>
          </group>
          <group group_id="O15">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O16">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O17">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience at Least One TEAE Related to 12-lead Electrocardiogram (ECG)</title>
          <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="13"/>
                <count group_id="O15" value="4"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience at Least One TEAE Related to Clinical Laboratory Tests</title>
        <time_frame>Baseline up to Day 7</time_frame>
        <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1-2: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in Group A to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S1-S2: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O11">
            <title>Part 1 Cohort 3: Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O12">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O13">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
          <group group_id="O14">
            <title>Part 2 Cohort 5-7: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy in Cohort 5 to 7 under 2-period crossover design.</description>
          </group>
          <group group_id="O15">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O16">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O17">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience at Least One TEAE Related to Clinical Laboratory Tests</title>
          <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="13"/>
                <count group_id="O15" value="4"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or cerebrospinal fluid (CSF) concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or cerebrospinal fluid (CSF) concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.0" spread="22.546"/>
                    <measurement group_id="O2" value="323.1" spread="45.793"/>
                    <measurement group_id="O3" value="513.3" spread="81.392"/>
                    <measurement group_id="O4" value="1055" spread="178.49"/>
                    <measurement group_id="O5" value="2069" spread="298.89"/>
                    <measurement group_id="O6" value="2655" spread="495.32"/>
                    <measurement group_id="O7" value="2994" spread="164.73"/>
                    <measurement group_id="O8" value="4542" spread="698.25"/>
                    <measurement group_id="O9" value="2546" spread="274.48"/>
                    <measurement group_id="O10" value="2011" spread="195.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.10" spread="31.837"/>
                    <measurement group_id="O2" value="170.7" spread="50.607"/>
                    <measurement group_id="O3" value="293.1" spread="120.91"/>
                    <measurement group_id="O4" value="613.8" spread="218.79"/>
                    <measurement group_id="O5" value="1272" spread="409.93"/>
                    <measurement group_id="O6" value="1724" spread="596.04"/>
                    <measurement group_id="O7" value="1762" spread="204.30"/>
                    <measurement group_id="O8" value="3094" spread="740.81"/>
                    <measurement group_id="O9" value="1037" spread="343.80"/>
                    <measurement group_id="O10" value="996.3" spread="321.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3676" spread="0.89268"/>
                    <measurement group_id="O2" value="1.940" spread="2.5750"/>
                    <measurement group_id="O3" value="5.893" spread="2.8201"/>
                    <measurement group_id="O4" value="9.225" spread="6.3231"/>
                    <measurement group_id="O5" value="22.79" spread="19.464"/>
                    <measurement group_id="O6" value="31.23" spread="25.058"/>
                    <measurement group_id="O7" value="28.69" spread="4.9460"/>
                    <measurement group_id="O8" value="56.79" spread="21.993"/>
                    <measurement group_id="O9" value="15.96" spread="9.4609"/>
                    <measurement group_id="O10" value="16.81" spread="8.7980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="910.8" spread="275.10"/>
                    <measurement group_id="O2" value="198.7" spread="13.540"/>
                    <measurement group_id="O3" value="86.15" spread="14.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="623.6" spread="516.16"/>
                    <measurement group_id="O2" value="100.7" spread="55.904"/>
                    <measurement group_id="O3" value="52.25" spread="17.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.90" spread="22.384"/>
                    <measurement group_id="O2" value="3.435" spread="2.0430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.8" spread="22.744"/>
                    <measurement group_id="O2" value="328.1" spread="51.138"/>
                    <measurement group_id="O3" value="523.5" spread="88.288"/>
                    <measurement group_id="O4" value="1065" spread="187.70"/>
                    <measurement group_id="O5" value="2092" spread="319.85"/>
                    <measurement group_id="O6" value="2682" spread="519.45"/>
                    <measurement group_id="O7" value="3013" spread="160.21"/>
                    <measurement group_id="O8" value="4585" spread="689.28"/>
                    <measurement group_id="O9" value="2590" spread="283.03"/>
                    <measurement group_id="O10" value="2028" spread="196.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.77" spread="32.409"/>
                    <measurement group_id="O2" value="173.5" spread="53.475"/>
                    <measurement group_id="O3" value="296.1" spread="122.50"/>
                    <measurement group_id="O4" value="618.9" spread="221.98"/>
                    <measurement group_id="O5" value="1284" spread="409.94"/>
                    <measurement group_id="O6" value="1737" spread="606.78"/>
                    <measurement group_id="O7" value="1764" spread="202.65"/>
                    <measurement group_id="O8" value="3112" spread="745.48"/>
                    <measurement group_id="O9" value="1052" spread="350.05"/>
                    <measurement group_id="O10" value="1001" spread="323.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.900"/>
                    <measurement group_id="O2" value="5.302" spread="1.6898"/>
                    <measurement group_id="O3" value="6.416" spread="1.0512"/>
                    <measurement group_id="O4" value="9.796" spread="6.6369"/>
                    <measurement group_id="O5" value="23.79" spread="19.535"/>
                    <measurement group_id="O6" value="32.29" spread="25.766"/>
                    <measurement group_id="O7" value="29.43" spread="5.0744"/>
                    <measurement group_id="O8" value="57.72" spread="21.853"/>
                    <measurement group_id="O9" value="16.88" spread="9.9205"/>
                    <measurement group_id="O10" value="17.22" spread="8.8861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="925.3" spread="296.03"/>
                    <measurement group_id="O2" value="200.7" spread="13.216"/>
                    <measurement group_id="O3" value="88.45" spread="13.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="634.0" spread="549.20"/>
                    <measurement group_id="O2" value="102.4" spread="55.929"/>
                    <measurement group_id="O3" value="54.77" spread="17.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.99" spread="28.284"/>
                    <measurement group_id="O2" value="3.816" spread="0.60811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, Cmax: Maximum Observed Plasma Concentration for TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, Cmax: Maximum Observed Plasma Concentration for TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.70" spread="2.8896"/>
                    <measurement group_id="O2" value="36.83" spread="4.3976"/>
                    <measurement group_id="O3" value="57.56" spread="8.2309"/>
                    <measurement group_id="O4" value="122.6" spread="13.014"/>
                    <measurement group_id="O5" value="235.2" spread="40.712"/>
                    <measurement group_id="O6" value="304.9" spread="50.702"/>
                    <measurement group_id="O7" value="344.5" spread="23.549"/>
                    <measurement group_id="O8" value="506.3" spread="87.027"/>
                    <measurement group_id="O9" value="278.4" spread="33.127"/>
                    <measurement group_id="O10" value="237.8" spread="25.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.458" spread="3.5972"/>
                    <measurement group_id="O2" value="19.50" spread="4.9426"/>
                    <measurement group_id="O3" value="31.82" spread="11.983"/>
                    <measurement group_id="O4" value="67.69" spread="20.931"/>
                    <measurement group_id="O5" value="134.1" spread="45.828"/>
                    <measurement group_id="O6" value="189.2" spread="60.185"/>
                    <measurement group_id="O7" value="197.8" spread="26.011"/>
                    <measurement group_id="O8" value="333.2" spread="70.509"/>
                    <measurement group_id="O9" value="106.7" spread="30.612"/>
                    <measurement group_id="O10" value="114.4" spread="38.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2379" spread="0.11806"/>
                    <measurement group_id="O2" value="0.4290" spread="0.24813"/>
                    <measurement group_id="O3" value="0.7051" spread="0.33672"/>
                    <measurement group_id="O4" value="1.076" spread="0.63619"/>
                    <measurement group_id="O5" value="2.564" spread="2.0370"/>
                    <measurement group_id="O6" value="3.422" spread="2.4880"/>
                    <measurement group_id="O7" value="3.279" spread="0.53902"/>
                    <measurement group_id="O8" value="6.611" spread="2.2350"/>
                    <measurement group_id="O9" value="1.751" spread="0.90125"/>
                    <measurement group_id="O10" value="2.022" spread="0.99882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, Cmax: Maximum Observed Plasma Concentration for TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, Cmax: Maximum Observed Plasma Concentration for TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.48" spread="21.981"/>
                    <measurement group_id="O2" value="21.86" spread="2.5303"/>
                    <measurement group_id="O3" value="10.10" spread="1.9527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.28" spread="39.990"/>
                    <measurement group_id="O2" value="11.23" spread="5.0467"/>
                    <measurement group_id="O3" value="5.990" spread="1.8931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.305" spread="1.9483"/>
                    <measurement group_id="O2" value="0.4884" spread="0.28306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, Ceoi: Concentration at the End of Infusion for TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, Ceoi: Concentration at the End of Infusion for TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.37" spread="2.0174"/>
                    <measurement group_id="O2" value="29.81" spread="4.2579"/>
                    <measurement group_id="O3" value="52.08" spread="7.2344"/>
                    <measurement group_id="O4" value="114.6" spread="13.303"/>
                    <measurement group_id="O5" value="213.8" spread="31.714"/>
                    <measurement group_id="O6" value="290.3" spread="32.096"/>
                    <measurement group_id="O7" value="324.0" spread="30.182"/>
                    <measurement group_id="O8" value="493.2" spread="70.335"/>
                    <measurement group_id="O9" value="272.2" spread="36.985"/>
                    <measurement group_id="O10" value="183.5" spread="15.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.532" spread="3.4019"/>
                    <measurement group_id="O2" value="17.79" spread="4.9179"/>
                    <measurement group_id="O3" value="28.06" spread="11.208"/>
                    <measurement group_id="O4" value="58.79" spread="23.607"/>
                    <measurement group_id="O5" value="121.3" spread="37.632"/>
                    <measurement group_id="O6" value="167.5" spread="58.242"/>
                    <measurement group_id="O7" value="174.0" spread="20.376"/>
                    <measurement group_id="O8" value="295.5" spread="75.002"/>
                    <measurement group_id="O9" value="98.82" spread="31.862"/>
                    <measurement group_id="O10" value="105.0" spread="38.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2289" spread="0.12885"/>
                    <measurement group_id="O2" value="0.3978" spread="0.23853"/>
                    <measurement group_id="O3" value="0.5928" spread="0.27538"/>
                    <measurement group_id="O4" value="0.9225" spread="0.54081"/>
                    <measurement group_id="O5" value="2.217" spread="1.6608"/>
                    <measurement group_id="O6" value="3.079" spread="2.3329"/>
                    <measurement group_id="O7" value="2.850" spread="0.52592"/>
                    <measurement group_id="O8" value="4.868" spread="2.3897"/>
                    <measurement group_id="O9" value="1.528" spread="0.87452"/>
                    <measurement group_id="O10" value="1.624" spread="0.96722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, Ceoi: Concentration at the End of Infusion for TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, Ceoi: Concentration at the End of Infusion for TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.04" spread="23.643"/>
                    <measurement group_id="O2" value="21.17" spread="1.7896"/>
                    <measurement group_id="O3" value="9.649" spread="1.1339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.61" spread="42.471"/>
                    <measurement group_id="O2" value="9.916" spread="5.6434"/>
                    <measurement group_id="O3" value="5.412" spread="1.7517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.075" spread="1.8500"/>
                    <measurement group_id="O2" value="0.4037" spread="0.23357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.000" lower_limit="3.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.000" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="4.000" lower_limit="3.00" upper_limit="9.00"/>
                    <measurement group_id="O5" value="4.000" lower_limit="1.50" upper_limit="9.00"/>
                    <measurement group_id="O6" value="6.500" lower_limit="3.00" upper_limit="9.00"/>
                    <measurement group_id="O7" value="6.500" lower_limit="3.00" upper_limit="9.00"/>
                    <measurement group_id="O8" value="4.000" lower_limit="3.00" upper_limit="9.00"/>
                    <measurement group_id="O9" value="6.500" lower_limit="1.50" upper_limit="9.00"/>
                    <measurement group_id="O10" value="5.000" lower_limit="3.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.000" lower_limit="6.00" upper_limit="9.00"/>
                    <measurement group_id="O2" value="6.000" lower_limit="6.00" upper_limit="9.00"/>
                    <measurement group_id="O3" value="6.000" lower_limit="6.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="6.000" lower_limit="6.00" upper_limit="9.00"/>
                    <measurement group_id="O5" value="6.000" lower_limit="6.00" upper_limit="9.00"/>
                    <measurement group_id="O6" value="6.000" lower_limit="6.00" upper_limit="8.00"/>
                    <measurement group_id="O7" value="6.000" lower_limit="6.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="6.000" lower_limit="6.00" upper_limit="6.00"/>
                    <measurement group_id="O9" value="6.000" lower_limit="6.00" upper_limit="6.000"/>
                    <measurement group_id="O10" value="8.000" lower_limit="8.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.500" lower_limit="4.00" upper_limit="9.00"/>
                    <measurement group_id="O2" value="8.000" lower_limit="6.00" upper_limit="9.00"/>
                    <measurement group_id="O3" value="4.000" lower_limit="4.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="6.000" lower_limit="4.00" upper_limit="9.00"/>
                    <measurement group_id="O5" value="4.000" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="4.000" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O7" value="5.000" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="3.500" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O9" value="3.000" lower_limit="1.50" upper_limit="9.00"/>
                    <measurement group_id="O10" value="3.500" lower_limit="1.50" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.500" lower_limit="4.00" upper_limit="9.00"/>
                    <measurement group_id="O2" value="9.000" lower_limit="4.00" upper_limit="9.00"/>
                    <measurement group_id="O3" value="9.000" lower_limit="4.00" upper_limit="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.000" lower_limit="6.00" upper_limit="9.00"/>
                    <measurement group_id="O2" value="6.000" lower_limit="6.00" upper_limit="9.00"/>
                    <measurement group_id="O3" value="6.000" lower_limit="6.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.960" lower_limit="4.00" upper_limit="9.00"/>
                    <measurement group_id="O2" value="5.990" lower_limit="5.98" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, t1/2z: Terminal Disposition Phase Half-life of TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, t1/2z: Terminal Disposition Phase Half-life of TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.120" spread="1.9190"/>
                    <measurement group_id="O2" value="4.498" spread="1.7725"/>
                    <measurement group_id="O3" value="5.142" spread="1.8060"/>
                    <measurement group_id="O4" value="3.860" spread="0.6478"/>
                    <measurement group_id="O5" value="3.788" spread="1.0424"/>
                    <measurement group_id="O6" value="3.943" spread="0.9492"/>
                    <measurement group_id="O7" value="3.363" spread="0.8523"/>
                    <measurement group_id="O8" value="4.033" spread="1.2843"/>
                    <measurement group_id="O9" value="4.345" spread="0.5901"/>
                    <measurement group_id="O10" value="4.490" spread="1.5939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.598" spread="1.3239"/>
                    <measurement group_id="O2" value="3.443" spread="0.9386"/>
                    <measurement group_id="O3" value="3.122" spread="0.4673"/>
                    <measurement group_id="O4" value="2.760" spread="0.8950"/>
                    <measurement group_id="O5" value="3.075" spread="0.5984"/>
                    <measurement group_id="O6" value="2.825" spread="0.5203"/>
                    <measurement group_id="O7" value="2.205" spread="0.2616"/>
                    <measurement group_id="O8" value="2.637" spread="0.5575"/>
                    <measurement group_id="O9" value="3.763" spread="0.7675"/>
                    <measurement group_id="O10" value="2.400" spread="0.6307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.670"/>
                    <measurement group_id="O2" value="1.8975" spread="0.2583"/>
                    <measurement group_id="O3" value="1.545" spread="0.1237"/>
                    <measurement group_id="O4" value="1.692" spread="0.7082"/>
                    <measurement group_id="O5" value="2.158" spread="0.7646"/>
                    <measurement group_id="O6" value="2.847" spread="1.5995"/>
                    <measurement group_id="O7" value="1.702" spread="0.4891"/>
                    <measurement group_id="O8" value="2.818" spread="1.0856"/>
                    <measurement group_id="O9" value="2.727" spread="1.3977"/>
                    <measurement group_id="O10" value="1.205" spread="0.2873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, t1/2z: Terminal Disposition Phase Half-life of TAK-925 and Its Metabolites M1 and M2</title>
        <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, t1/2z: Terminal Disposition Phase Half-life of TAK-925 and Its Metabolites M1 and M2</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.130" spread="1.1981"/>
                    <measurement group_id="O2" value="3.923" spread="1.0265"/>
                    <measurement group_id="O3" value="3.465" spread="1.0998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.670" spread="0.9131"/>
                    <measurement group_id="O2" value="2.523" spread="1.0892"/>
                    <measurement group_id="O3" value="2.154" spread="0.4215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.120" spread="2.5032"/>
                    <measurement group_id="O2" value="0.915" spread="0.2192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-925</title>
        <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-925</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.88" spread="29.543"/>
                    <measurement group_id="O2" value="77.07" spread="22.804"/>
                    <measurement group_id="O3" value="116.1" spread="35.215"/>
                    <measurement group_id="O4" value="91.40" spread="14.122"/>
                    <measurement group_id="O5" value="97.83" spread="22.194"/>
                    <measurement group_id="O6" value="88.47" spread="12.476"/>
                    <measurement group_id="O7" value="90.75" spread="24.140"/>
                    <measurement group_id="O8" value="97.48" spread="28.378"/>
                    <measurement group_id="O9" value="99.48" spread="15.472"/>
                    <measurement group_id="O10" value="77.98" spread="28.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-925</title>
        <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-925</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.8" spread="7.8049"/>
                    <measurement group_id="O2" value="114.1" spread="14.964"/>
                    <measurement group_id="O3" value="111.7" spread="26.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, Vz: Volume of Distribution During the Terminal Phase After Intravenous Administration for TAK-925</title>
        <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, Vz: Volume of Distribution During the Terminal Phase After Intravenous Administration for TAK-925</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292.2" spread="124.03"/>
                    <measurement group_id="O2" value="271.7" spread="79.238"/>
                    <measurement group_id="O3" value="391.8" spread="117.09"/>
                    <measurement group_id="O4" value="290.7" spread="31.156"/>
                    <measurement group_id="O5" value="288.8" spread="55.185"/>
                    <measurement group_id="O6" value="284.7" spread="65.265"/>
                    <measurement group_id="O7" value="290.8" spread="77.783"/>
                    <measurement group_id="O8" value="313.0" spread="128.81"/>
                    <measurement group_id="O9" value="271.5" spread="39.145"/>
                    <measurement group_id="O10" value="357.3" spread="121.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, Vz: Volume of Distribution During the Terminal Phase After Intravenous Administration for TAK-925</title>
        <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, Vz: Volume of Distribution During the Terminal Phase After Intravenous Administration for TAK-925</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.3" spread="35.855"/>
                    <measurement group_id="O2" value="316.8" spread="84.263"/>
                    <measurement group_id="O3" value="282.3" spread="88.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, CL: Total Clearance After Intravenous Administration for TAK-925</title>
        <time_frame>Day 1 pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 9 hours after the start of infusion and at 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 10 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, CL: Total Clearance After Intravenous Administration for TAK-925</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
          <units>liter per hour (L/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00" spread="9.0785"/>
                    <measurement group_id="O2" value="43.07" spread="6.4856"/>
                    <measurement group_id="O3" value="54.20" spread="9.9541"/>
                    <measurement group_id="O4" value="53.10" spread="8.2202"/>
                    <measurement group_id="O5" value="54.10" spread="9.0437"/>
                    <measurement group_id="O6" value="50.90" spread="9.8018"/>
                    <measurement group_id="O7" value="59.83" spread="3.3381"/>
                    <measurement group_id="O8" value="52.78" spread="7.4882"/>
                    <measurement group_id="O9" value="43.50" spread="4.9651"/>
                    <measurement group_id="O10" value="55.40" spread="5.2211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, CL: Total Clearance After Intravenous Administration for TAK-925</title>
        <time_frame>Days 1-4 pre-infusion and at 1, 2, 4, 6 and 9 hours after the start of infusion and at 0.17, 0.5, 1, 2 and 15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, CL: Total Clearance After Intravenous Administration for TAK-925</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.18" spread="15.533"/>
                    <measurement group_id="O2" value="55.90" spread="3.7692"/>
                    <measurement group_id="O3" value="57.05" spread="9.5577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, Ae(0-24): Amount of TAK-925 and Its Metabolites M1 and M2 Excreted in Urine From Time 0 to Time 24</title>
        <description>Urine assessments were done only in Part 1, as planned.</description>
        <time_frame>Day 1 pre-infusion and 0-9 hours after the start of infusion and at 0-3, 3-6, 6-15 and 15-24 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, Ae(0-24): Amount of TAK-925 and Its Metabolites M1 and M2 Excreted in Urine From Time 0 to Time 24</title>
          <description>Urine assessments were done only in Part 1, as planned.</description>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
          <units>microgram (mcg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.892" spread="0.93889"/>
                    <measurement group_id="O2" value="5.460" spread="3.4291"/>
                    <measurement group_id="O3" value="14.10" spread="2.4515"/>
                    <measurement group_id="O4" value="60.87" spread="23.008"/>
                    <measurement group_id="O5" value="210.5" spread="75.775"/>
                    <measurement group_id="O6" value="335.8" spread="117.81"/>
                    <measurement group_id="O7" value="578.5" spread="110.30"/>
                    <measurement group_id="O8" value="1223" spread="76.855"/>
                    <measurement group_id="O9" value="214.3" spread="137.61"/>
                    <measurement group_id="O10" value="184.8" spread="53.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.8" spread="49.600"/>
                    <measurement group_id="O2" value="426.7" spread="101.25"/>
                    <measurement group_id="O3" value="792.8" spread="253.36"/>
                    <measurement group_id="O4" value="1697" spread="495.32"/>
                    <measurement group_id="O5" value="1905" spread="1490.9"/>
                    <measurement group_id="O6" value="5228" spread="1785.9"/>
                    <measurement group_id="O7" value="5815" spread="1095.4"/>
                    <measurement group_id="O8" value="8163" spread="945.57"/>
                    <measurement group_id="O9" value="2343" spread="635.69"/>
                    <measurement group_id="O10" value="3193" spread="677.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="1.152" spread="1.5202"/>
                    <measurement group_id="O3" value="2.438" spread="2.2612"/>
                    <measurement group_id="O4" value="8.695" spread="5.3533"/>
                    <measurement group_id="O5" value="31.25" spread="26.282"/>
                    <measurement group_id="O6" value="40.08" spread="28.904"/>
                    <measurement group_id="O7" value="43.12" spread="8.4203"/>
                    <measurement group_id="O8" value="79.90" spread="23.679"/>
                    <measurement group_id="O9" value="14.37" spread="6.0079"/>
                    <measurement group_id="O10" value="21.01" spread="10.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, Fe(0-24): Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time 24 for TAK-925 and Its Metabolites M1 and M2</title>
        <description>Urine assessments were done only in Part 1, as planned.</description>
        <time_frame>Day 1 pre-infusion and 0-9 hours after the start of infusion and at 0-3, 3-6, 6-15 and 15-24 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, Fe(0-24): Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time 24 for TAK-925 and Its Metabolites M1 and M2</title>
          <description>Urine assessments were done only in Part 1, as planned.</description>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;overall participants analyzed&quot; are participants who were available for this outcome measure assessment at given time period.</population>
          <units>percentage of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" spread="0.0148"/>
                    <measurement group_id="O2" value="0.038" spread="0.0232"/>
                    <measurement group_id="O3" value="0.050" spread="0.0071"/>
                    <measurement group_id="O4" value="0.110" spread="0.0424"/>
                    <measurement group_id="O5" value="0.190" spread="0.0657"/>
                    <measurement group_id="O6" value="0.250" spread="0.0883"/>
                    <measurement group_id="O7" value="0.322" spread="0.0624"/>
                    <measurement group_id="O8" value="0.508" spread="0.0319"/>
                    <measurement group_id="O9" value="0.192" spread="0.1237"/>
                    <measurement group_id="O10" value="0.165" spread="0.0480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.736" spread="0.6841"/>
                    <measurement group_id="O2" value="2.938" spread="0.6950"/>
                    <measurement group_id="O3" value="2.726" spread="0.8677"/>
                    <measurement group_id="O4" value="2.920" spread="0.8519"/>
                    <measurement group_id="O5" value="3.358" spread="1.2922"/>
                    <measurement group_id="O6" value="3.748" spread="1.2809"/>
                    <measurement group_id="O7" value="3.112" spread="0.5872"/>
                    <measurement group_id="O8" value="3.280" spread="0.3788"/>
                    <measurement group_id="O9" value="2.015" spread="0.5452"/>
                    <measurement group_id="O10" value="2.748" spread="0.5871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.008" spread="0.0117"/>
                    <measurement group_id="O3" value="0.008" spread="0.0084"/>
                    <measurement group_id="O4" value="0.017" spread="0.0103"/>
                    <measurement group_id="O5" value="0.025" spread="0.0243"/>
                    <measurement group_id="O6" value="0.028" spread="0.0214"/>
                    <measurement group_id="O7" value="0.023" spread="0.0052"/>
                    <measurement group_id="O8" value="0.032" spread="0.0117"/>
                    <measurement group_id="O9" value="0.013" spread="0.0082"/>
                    <measurement group_id="O10" value="0.018" spread="0.0096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, CLR: Renal Clearance of TAK-925 and Its Metabolites M1 and M2</title>
        <description>Urine assessments were done only in Part 1, as planned.</description>
        <time_frame>Day 1 pre-infusion and 0-9 hours after the start of infusion and at 0-3, 3-6 and 6-15 hours post-infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-925 7 mg</title>
            <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-925 14 mg</title>
            <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 1: TAK-925 28 mg</title>
            <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O4">
            <title>Par 1 Cohort 2: TAK-925 56 mg</title>
            <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 1: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
            <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort S1: TAK-925 180 mg</title>
            <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort S2: TAK-925 240 mg</title>
            <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 3: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, CLR: Renal Clearance of TAK-925 and Its Metabolites M1 and M2</title>
          <description>Urine assessments were done only in Part 1, as planned.</description>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated. Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01390" spread="0.0071503"/>
                    <measurement group_id="O2" value="0.01656" spread="0.0097578"/>
                    <measurement group_id="O3" value="0.02746" spread="0.0053337"/>
                    <measurement group_id="O4" value="0.05672" spread="0.018842"/>
                    <measurement group_id="O5" value="0.1020" spread="0.037350"/>
                    <measurement group_id="O6" value="0.1275" spread="0.046864"/>
                    <measurement group_id="O7" value="0.1928" spread="0.035244"/>
                    <measurement group_id="O8" value="0.2705" spread="0.031501"/>
                    <measurement group_id="O9" value="0.08337" spread="0.053779"/>
                    <measurement group_id="O10" value="0.09053" spread="0.018093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.664" spread="0.83930"/>
                    <measurement group_id="O2" value="2.438" spread="0.30142"/>
                    <measurement group_id="O3" value="2.614" spread="0.54500"/>
                    <measurement group_id="O4" value="2.653" spread="0.24138"/>
                    <measurement group_id="O5" value="2.952" spread="0.65615"/>
                    <measurement group_id="O6" value="2.878" spread="0.35459"/>
                    <measurement group_id="O7" value="3.285" spread="0.49152"/>
                    <measurement group_id="O8" value="2.643" spread="0.37012"/>
                    <measurement group_id="O9" value="2.205" spread="0.35172"/>
                    <measurement group_id="O10" value="3.173" spread="0.50684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.2182" spread="0.25950"/>
                    <measurement group_id="O3" value="0.4630" spread="0.31605"/>
                    <measurement group_id="O4" value="0.7897" spread="0.077544"/>
                    <measurement group_id="O5" value="1.014" spread="0.23516"/>
                    <measurement group_id="O6" value="1.041" spread="0.12104"/>
                    <measurement group_id="O7" value="1.468" spread="0.20508"/>
                    <measurement group_id="O8" value="1.353" spread="0.12894"/>
                    <measurement group_id="O9" value="0.7967" spread="0.15368"/>
                    <measurement group_id="O10" value="1.132" spread="0.24401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1, R(CSF/Plasma,ss): Cerebrospinal Fluid/Plasma Drug Concentration at Steady State for TAK-925 and Its Metabolites M1 and M2 in Cohort 4</title>
        <time_frame>Day 1 at 6 hours after start of infusion</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 4: TAK-925 112 mg</title>
            <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, R(CSF/Plasma,ss): Cerebrospinal Fluid/Plasma Drug Concentration at Steady State for TAK-925 and Its Metabolites M1 and M2 in Cohort 4</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug and whose plasma or CSF concentration was measured at least once or whose cumulative urinary excretion was calculated.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-925</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02848" spread="0.0056258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06190" spread="0.010358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02818" spread="0.032718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Average Sleep Latency in Maintenance of Wakefulness Test (MWT)</title>
        <description>The MWT is a validated objective measure that evaluates a person's ability to remain awake under soporific conditions for a defined period of time. This tendency to fall asleep is measured via electroencephalography-derived sleep latency. Sleep onset is defined as the first epoch of greater than 15 seconds of cumulative sleep in a 30-second epoch. Trials were ended after 40 minutes if no sleep occurs, or after unequivocal sleep, defined as 3 consecutive epochs of stage 1 sleep, or 1 epoch of any other stage of sleep. If no sleep has been observed according to these rules, then the latency is defined as 40 minutes. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake.</description>
        <time_frame>Days 1 and 3 up to 8 hours following the start of infusion</time_frame>
        <population>The pharmacodynamic analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 5-7: Pooled Placebo</title>
            <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy in Cohort 5 to 7 under 2-period crossover design.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
            <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
            <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 7: TAK-925 5 mg</title>
            <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Average Sleep Latency in Maintenance of Wakefulness Test (MWT)</title>
          <description>The MWT is a validated objective measure that evaluates a person's ability to remain awake under soporific conditions for a defined period of time. This tendency to fall asleep is measured via electroencephalography-derived sleep latency. Sleep onset is defined as the first epoch of greater than 15 seconds of cumulative sleep in a 30-second epoch. Trials were ended after 40 minutes if no sleep occurs, or after unequivocal sleep, defined as 3 consecutive epochs of stage 1 sleep, or 1 epoch of any other stage of sleep. If no sleep has been observed according to these rules, then the latency is defined as 40 minutes. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake.</description>
          <population>The pharmacodynamic analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="1.646"/>
                    <measurement group_id="O2" value="40.00" spread="0.000"/>
                    <measurement group_id="O3" value="37.59" spread="4.813"/>
                    <measurement group_id="O4" value="22.38" spread="10.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value for each treatment group is for the comparison of that treatment group to the placebo treatment group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value for each treatment group is for the comparison of that treatment group to the placebo treatment group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>The p-value for each treatment group is for the comparison of that treatment group to the placebo treatment group.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 7 days (Day 7) after the last dose of study drug</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1 Cohort 1-2: Pooled Placebo</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in Group A to H in double-blind, alternating panel.</description>
        </group>
        <group group_id="E2">
          <title>Part 1 Cohort 1: TAK-925 7 mg</title>
          <description>TAK-925 7 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
        </group>
        <group group_id="E3">
          <title>Part 1 Cohort 2: TAK-925 14 mg</title>
          <description>TAK-925 14 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
        </group>
        <group group_id="E4">
          <title>Part 1 Cohort 1: TAK-925 28 mg</title>
          <description>TAK-925 28 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
        </group>
        <group group_id="E5">
          <title>Par 1 Cohort 2: TAK-925 56 mg</title>
          <description>TAK-925 56 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
        </group>
        <group group_id="E6">
          <title>Part 1 Cohort 1: TAK-925 112 mg</title>
          <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in Group A to D in double-blind, alternating panel.</description>
        </group>
        <group group_id="E7">
          <title>Part 1 Cohort 2: TAK-925 134.4 mg</title>
          <description>TAK-925 134.4 mg, infusion, intravenously, once on Day 1 in healthy adults in Group E to H in double-blind, alternating panel.</description>
        </group>
        <group group_id="E8">
          <title>Part 1 Cohort S1-S2: Pooled Placebo</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
        </group>
        <group group_id="E9">
          <title>Part 1 Cohort S1: TAK-925 180 mg</title>
          <description>TAK-925 180 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
        </group>
        <group group_id="E10">
          <title>Part 1 Cohort S2: TAK-925 240 mg</title>
          <description>TAK-925 240 mg, infusion, intravenously, once on Day 1 in healthy adults in double-blind, parallel group.</description>
        </group>
        <group group_id="E11">
          <title>Part 1 Cohort 3: Placebo</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
        </group>
        <group group_id="E12">
          <title>Part 1 Cohort 3: TAK-925 112 mg</title>
          <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy elderly participants in double-blind, parallel group.</description>
        </group>
        <group group_id="E13">
          <title>Part 1 Cohort 4: TAK-925 112 mg</title>
          <description>TAK-925 112 mg, infusion, intravenously, once on Day 1 in healthy adults in unblinded manner.</description>
        </group>
        <group group_id="E14">
          <title>Part 2 Cohort 5-7: Pooled Placebo</title>
          <description>TAK-925 placebo-matching infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy in Cohort 5 to 7 under 2-period crossover design.</description>
        </group>
        <group group_id="E15">
          <title>Part 2 Cohort 5: TAK-925 44.8 mg</title>
          <description>TAK-925 44.8 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
        </group>
        <group group_id="E16">
          <title>Part 2 Cohort 6: TAK-925 11.2 mg</title>
          <description>TAK-925 11.2 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
        </group>
        <group group_id="E17">
          <title>Part 2 Cohort 7: TAK-925 5 mg</title>
          <description>TAK-925 5 mg, infusion, intravenously, once on Day 1 or Day 3 in participants with type 1 narcolepsy under 2-period crossover design.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling drunk</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Electrocardiogram PR prolongation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Narcolepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypnagogic hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Logorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

